Gidal Barry E, Tamura T, Hammer Anne, Vuong Alain
School of Pharmacy and Department of Neurology, University of Wisconsin, 777 Highland Ave., Madison, WI 53705, USA.
Epilepsy Res. 2005 May;64(3):161-6. doi: 10.1016/j.eplepsyres.2005.03.005.
To evaluate whether the administration of lamotrigine (LTG) or valproate (VPA) changes concentrations of plasma total homocysteine (tHcy), plasma and red-cell folate and plasma Vitamin B-12, we measured these indices in a total of 20 patients with epilepsy before and after a 32-week period of monotherapy of LTG or VPA. We found that the 32-week administration of a mean daily dose of 250mg LTG had no significant effect on any of the blood indices. On the other hand, the administration of a mean daily dose of 2070mg of VPA resulted in a 57% increase in plasma Vitamin B-12 concentrations over the baseline value and a 27% decline in plasma tHcy concentrations, although the mechanisms of such changes are unknown. Our data indicate that hyperhomocysteinemia may not be a serious clinical problem among patients with epilepsy, who receive either LTG or VPA.
为评估拉莫三嗪(LTG)或丙戊酸盐(VPA)的给药是否会改变血浆总同型半胱氨酸(tHcy)、血浆和红细胞叶酸以及血浆维生素B-12的浓度,我们在20例癫痫患者接受LTG或VPA单药治疗32周前后测量了这些指标。我们发现,平均每日剂量250mg的LTG给药32周对任何血液指标均无显著影响。另一方面,平均每日剂量2070mg的VPA给药导致血浆维生素B-12浓度较基线值升高57%,血浆tHcy浓度下降27%,尽管这种变化的机制尚不清楚。我们的数据表明,高同型半胱氨酸血症在接受LTG或VPA治疗的癫痫患者中可能不是一个严重的临床问题。